Catalyst Pharmaceuticals, Inc.

CPRX • Biotechnology

$31.49

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL MUY FAVORABLEExcelenteConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$4.00B

Crecimiento

—

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 36.4%Crecimiento positivo de ingresos · 37.1%Flujo de caja libre positivo · 1.71Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 13.32

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 11 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 6 ago 2026, 1:54 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$31.49

Change0.00%

Shares Out126.90M

Market Cap$4.00B

Enterprise Value$3.24B

52W Range19.05 - 32.56

Beta0.74

P/E18.06

P/S6.69

P/B3.95

P/FCF19.20

EV/Sales5.43

Price$31.49

Change0.00%

Shares Out126.90M

Market Cap$4.00B

Enterprise Value$3.24B

52W Range19.05 - 32.56

Beta0.74

P/E18.06

P/S6.69

P/B3.95

P/FCF19.20

EV/Sales5.43

EV/EBITDA10.33

EV/FCF15.57

Earnings Yield5.54%

FCF Yield5.21%

Dividend Yield0.00%

Gross Margin85.19%

Oper. Margin43.77%

Profit Margin36.39%

Debt/Eq0.00

Current Ratio6.08

Quick Ratio5.82

Target$31.75

Target Upside0.83%

Target Median$31.75

Target Range31.50 - 32.00

Volume0.00

Avg Volume3.01M

EPS Surprise0.10

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

90/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

80/100

Por qué este puntaje▼

Márgenes estables o en mejora · 36.4%Crecimiento positivo de ingresos · 37.1%Flujo de caja libre positivo · 1.71Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 13.32Nivel de deuda manejable · 0

Analyst view

Analyst sentiment and price target

CPRX

Analyst sentiment

Based on 16 analyst votes · 2026-09-05

88/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-06

Bajo

$31.50

Promedio

$31.75

Mediana

$31.75

Alto

$32.00

Resumen de la compañía

IPO: 11/8/2006

Industria: Biotechnology

P/B i: 3.95

Deuda / Patrimonio i: 0.00

Margen operativo: 43.77%

Margen neto: 36.39%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 6.08

Ratio rápido: 5.82

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 6 venta interna de alto volumens detectadas

Kalb Michael Wayne

Transacción: 07/15/2026

VENTA

Cambio

-39,701

Precio

Not reported

Presentación

07/17/2026

Tipo

VENTA

Kalb Michael Wayne

Transacción: 07/15/2026

VENTA

Cambio

-131,536

Precio

$22.77

Presentación

07/17/2026

Tipo

VENTA

Kalb Michael Wayne

Transacción: 07/15/2026

VENTA

Cambio

-13,665

Precio

$31.50

Presentación

07/17/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Kalb Michael Wayne	VENTA	-39,701	Not reported	07/15/2026	07/17/2026
Kalb Michael Wayne	VENTA	-131,536	$22.77	07/15/2026	07/17/2026
Kalb Michael Wayne	VENTA	-13,665	$31.50	07/15/2026	07/17/2026
Harper Molly	VENTA	-5,468	Not reported	07/15/2026	07/17/2026
Harper Molly	VENTA	-18,115	$22.77	07/15/2026	07/17/2026
Harper Molly	VENTA	-3,694	$31.50	07/15/2026	07/17/2026
Andrews William T.	VENTA	-29,776	Not reported	07/15/2026	07/17/2026
Andrews William T.	VENTA	-98,652	$22.77	07/15/2026	07/17/2026
Andrews William T.	VENTA	-2,309	$31.50	07/15/2026	07/17/2026
Daly Richard J	VENTA	-115,283	Not reported	07/15/2026	07/17/2026
Daly Richard J	VENTA	-381,948	$22.77	07/15/2026	07/17/2026
Daly Richard J	VENTA	-271,266	$31.50	07/15/2026	07/17/2026
Sundaram Preethi	VENTA	-32,257	Not reported	07/15/2026	07/17/2026
Sundaram Preethi	VENTA	-106,873	$22.77	07/15/2026	07/17/2026
Sundaram Preethi	VENTA	-54,804	$31.50	07/15/2026	07/17/2026
Del Carmen Jeffrey	VENTA	-32,257	Not reported	07/15/2026	07/17/2026
Del Carmen Jeffrey	VENTA	-106,873	$22.77	07/15/2026	07/17/2026
Del Carmen Jeffrey	VENTA	-14,337	$31.50	07/15/2026	07/17/2026
DENKHAUS DONALD A	VENTA	-5,468	Not reported	07/15/2026	07/17/2026
DENKHAUS DONALD A	VENTA	-18,115	$22.77	07/15/2026	07/17/2026

Sobre la compañía

Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.

Fuente - Link

Competidores

ADPT AGIO APLS BEAM CDTX IDYA KNSA MLYS RXRX SRRK

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Chuck Royce's Second Quarter 2026 13F: Catalyst Pharmaceuticals Reduction Leads Portfolio Shifts

A Deep Dive into the Small-Cap Pioneer's Latest Moves, Including a -0.42% Impact from Exiting a Major StakeCharles M. Royce, a pioneer of small-cap investing an

GuruFocus

California State Teachers Retirement System Acquires 30,717 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

California State Teachers Retirement System raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 27.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 140,716 shares of the biopharmaceutical company's stock after purchasing an additional 30,717 shares during the quarter.

Defense World

Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst

Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal involving ‌Italian state lender CDP.

Reuters

Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals

The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst's product portfolio The transaction is being carried out with the participation of funds managed by Blackstone CDP Equity approves €1 billion investment in Angelini Pharma Italy remains a strategic production and scientific hub ROME and CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A.

GlobeNewsWire

Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger

Catalyst Pharmaceuticals NASDAQ: CPRX stockholders approved the company's proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company officials during the meeting.

MarketBeat

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-11	0.64	0.74	0.1
2026-02-25	0.42	0.68	0.26
2025-11-05	0.51	0.68	0.17
2025-08-06	0.58	0.68	0.1
2025-05-07	0.53	0.68	0.15
2025-02-26	0.32	0.7	0.38
2024-11-06	0.49	0.57	0.08
2024-08-07	0.42	0.56	0.14
2024-05-08	0.34	0.38	0.04
2024-02-28	0.48	0.53	0.05
2023-11-08	-0.24	-0.24	0
2023-08-09	0.25	0.33	0.08